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Effect of Varying Dose of UV Radiation on Mammalian Skin: Simulation 
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To better understand the dependence of the incidence 
of squamous cell carcinoma on changes in solar spectral 
distribution and dose regimen, we exposed SK-1 hairless 
mice to solar-simulating radiation (290-400 nm). Select-
ive UV filtration was accomplished by passing this ra-
diation through Schott WG-320 cutoff filters of 0, 0.5, 1.0, 
2.0, and 3.0 mm thickness. Minimal erythema doses 
(MED) were determined for each filter combination. 
Starting with 0.5 and with 0.9 MED, groups of 20 mice 
were irradiated 5 days per week; this was increased by 
20% increments (of the original dose) every 6th day for 
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40 days ("0.5 MED" and "0.9 MED" experimental groups, 
respectively). Other groups of mice were irradiated with 
the same incremental increases, starting at 6.5 J/cm2 
("equal dose" regimen). The salient results were: (1) 
shorter wavelength components appear to preferentially 
produce tumors; (2) resultant observable dose-response 
behavior for each regimen is a complicated function of 
concurrent "light" and "dark" reactions; (3) time-dose 
reciprocity is absent; and (4) there are no straightfor-
ward relationships among tumor efficiency, dose frac-
tionation, and spectral distribution of excitation radia-
Georgia 30310. 
Abbreviations: 
MED: minimal erythema dose 
SCC: squamous cell carcinoma 
UVA: long-wavelength ultraviolet radiation (320-400 nm) 
UVB: middle-wavelength ultraviolet radiation (290-320 nm) 
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tion. These results indicate that photocarcinogenesis i s 
a dynamic process, in which events that result in tumor 
growth compete with those that cause tumor regression. 
In recent years, there has emerged a deeper awareness of th e 
possible deleterious consequences in skin of excessive exposm·e 
to s unligh t. Numerous investigations (see [1] for review) have 
documented that solar UVB radiation plays a major role in 
inducing skin cancer. More recent studies [2-6) have demon-
strated that UV A, which is visibly more abunda nt in nature, 
not only augments UVB effects, but also causes damage in its 
own right [7). Because of these waveband interactions, th e 
spectral distribution of the radiation impinging on the skin is a 
critical parameter in determining qualitative and quantitative 
UV effects. 
Solar cutaneous car cinogenesis is a dynamic process in which 
processes that give rise to tumor formation compete simulta-
neously with those that cause regression to produce an overall 
observed result. Because of the dynamic nature of these 
processes, the manner in which the radiation is administered, 
i. e., the total dose and dose fractionation are also important 
param eters (see [8,9)). 
Ongoing and predicted stratospheric ozone depletion changes 
th e spectral distribu tion and dose fractionation of ambient solar 
UV radiation by increasing the UVB component while leaving 
t he UV A essentially constant. Ozone depletion would, therefore, 
be expected to significantly affect the frequency of skin cancer 
in a way that would markedly depend on spectral distribution, 
total dose and, dose fractionation. 
Studies to follow are aimed at developing a better under-
standing of the interrelationships between the above parame-
ters and the development of squamous cell carcinoma (SCC). 
Ozone depletion can be simulated by use of Schott WG-320 
cutoff filters of varying thickness, as was demonstrated by 
Forbes et al [8], who studied such effects in the hairless mouse 
under one fixed set of total dose and dose fractionation condi-
tions. We have studied tumor formation as a fun ction of wave-
length distribution, under several dose regimens. Our resul ts 
indicate that tumorigenesis is preferentially produced by wave-
lengths in the 300- 310 nm region and that it competes dynam-
ically with natural tumor regressive processes and tissue dam-
age due to sunbw·n. 
MATERIALS AND METHODS 
Energy Sources and M easurements 
A 1.6 kW xenon a rc sola r-simulating lamp which has been previous ly 
described [6) was used as the source. Energy output from this lamp 
system was measured by a calibrated E ppley Thermopile in conjunction 
with a Keithley millimicrovoltmeter (Model149). Schott WG 320 cutoff 
filters of 0, 0.5, 1.0, 2.0, and 3.0 mm thickness were placed between th e 
sow·ce and the irradia tion s ite . The spectral distribu tion of each filter 
combination (Fig 1) was measured with a calibrated spectroradiometer 
(Optronic Laboratories) in conjunction with a Hewlett-Packard Model 
9815 calculator. The tota l radiation outpu t from each of these combi-
nations ranged from 190 ± 30 mw/cm~ (for the 3.0-mm combination) to 
230 ± 25 mw/cm2 (for the " no fil ter" combination). 
Animals and Methods of Exposure 
Sk-1 hair less albino mice used for irradiation have been previously 
described [6]. Twenty 6- to 8-week-old mice were used for each filter 
combination/ dose regimen. For rad iation exposm e, animals were a f-
fixed to a plastic mouse boru·d and held in place with adhesive tape. 
T h e test s ite was approximately 1.5 em and located on the midback. 
For the chronic experiments, exposures were delivered to the same site 
on 5 consecutive days per week. Clinical observations were made daily, 
and responses were graded as follows: E, mild to moderate maculaJ· 
erythema; E~, intense maculru· erythema; 1+, light scaling accompany-
ing erythema; 2+, fmn scaling, palpable keratosis; 3+, ra ised palpable, 
keratotic plaque (<:=1 em diameter and 1-5 mm in height) to eru·ly 
malignant development as defined by Epstein et a l [10); 4+, papilloma 
or t umor (2::1 em in diameter and <:=5 mm in height ) corresponding to 
extensive malignant development. 
The 1+ through 4+ responses represent a continuum of cancerous 
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changes. The end poin t was taken as a 3+ or greater respon e (early 
SCC or carcinoma in sit u, as described by Epstein et a t [10]). T he main 
difference between the 3+ a nd 4+ respon es was that the 3+ quite 
often exhibited regression phenomena, whereas no regression was ob-
served with the frankly malignant 4+ response. TheE, and E 2 responses 
are not considered to be precancerous, but simply sunburn respon es. 
Minimal Erythema Dose (MED) Determination 
For each fi lter combination, 5 6-week-old mice were irrad iated at 
25% dose increments. E rythemal responses were noted 24 h after 
irradiation. The MED was taken as the exposure required to elicit 
barely visible minimal redness. Each set of experiments was repeated 
3 t imes. 
Chronic Irradiation Experiments 
The technique for rap id induction of SCC [6] was used. Briefly the 
daily dose was increased by 20% increments (based on the s~;·ting 
dose) every 6th day for 40 irradiation days. T his regimen maximized 
tumor formation and minimized burning. 
Initia l dosages were chosen on the basis of the results of the MED 
determinat ions (Table 1) . Three sets of experiments were carried out. 
Two studies involved irradiation under each filter condition at star t ing 
dosages, D o, equiva lent to 0.5 MED and to 0.9 MED respectively (these 
are referred to as "0.5 MED" and "0.9 MED" experiments). The other 
study was cruTied out using equal doses for each combination (Do= 6.5 
J / cm2). In these "equal dose" experi ments, the dosage conditions of 
1.0 
0. 10 
O.QJ 
N 
E 
u 
' 5 
E 
~ 0.00 1 
en 
z 
w 
1-
z 
290 
WAVELENGTH ( nm ) 
a. NO FILTER 
b.0.5 mm 
c. I.Omm 
d.2.0mm 
e .3.0mm 
FIG 1. Spectral distribution of 1.6 kW solar-simulator flitered 
through Schott WG -320 filters of various thicknesses: a., no filter b 
0.5-mm filter; c, 1.0-mm filter; d, 2.0-mm filter; e, 3.0-mm filter. T~tai 
energy output ranged from 230 ± 25 m W /cm2 (no fi lte r) to 190 ± 30 
mW /cm2 (3.0-mm filter). 
TABLE I. NIED for hairless mice irradiated with solar-simulating 
UV filtered through Schott WG-320 filters of varying thiclm esses 
WG-320 Filter thick· 1% Cutoff wavelength 
ness (mm) (nm) 
0 301.0 
0.5 303.5 
1.0 305.5 
2.0 307.5 
3.0 308.5 
MED ±S.D. (J /cm' ) 
7.1 ± 0.5 
13.4 ± l.l 
17.3±1.1 
22.4 ± 2.1 
25.7 ± 3.0 
See text for experimental details. Resul ts are mean ± SD of 3 
determinations. 
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the " no ftlter" combination duplicated t hose of the " no filter" comb i-
nation for t he 0.9 MED experiment (i.e., in t he "equal dose" experi -
ments, D., = 0.9 MED, with subsequen t doses being incr ementa lly 
mcreased as for the latter experimen t). S imilarly , t he dosage conditions 
for the 0.5-mm fil ter combination corresponded to those of the 0.5 
MED experiment with the 0.5-mm filter combination. The "eq ua l dose" 
experiments wit h the 1.0, 2.0, a nd 3.0 mm combinations represented 
0.37, 0.28, and 0.24 MED for t hese respective combinations. 
Histology 
Biopsy specimens were taken at various times du1·ing t he experimen t. 
Specimens were formalin fixed and prepared for routine hematoxylin 
and eosin staining. · 
RESULTS 
MED Determination 
. The doses required to elicit minimal erythema responses are 
given for each filter combination in Table I. Erythema is 
preferentially elicited by the shorter wavelengths. The most 
mal'ked effect occul'S in changing the 1% cutoff wavelength from 
301.0 to 303.5 nm (corresponding to "no filte1·" and 0.5-mm WG-
320 filters, respectively. 
Tumorigenesis Experiments 
Irradiation at equal doses: Irradiations were canied out for 
each filter combination starting with 6.5 J /cm2, and incremen-
tally increasing the daily dose as described a bove (total dose 
360 J/cm2). The "no filter" combination produced tumors (3+ 
or greater) as shown in Fig 2 (triangles) and the 0.5 mm tumor 
production was as illustrated in Fig 3A (dots). These results 
are further discussed in subsequent sections. The 1.0-3.0-mm 
fUter combination produced no tumors. In the 1.0-mm filter 
study, 75% of the mice eventually progressed to the 1 + stage, 
but only E 1 or E 2 responses were obtained for either the 2.0-
mm or 3.0-mm filter combinations. Under these "equal dose" 
conditions, shorter wavelengths were apparently more effective 
at producing tumors than are longer wavelengths (see below, 
however). 
Irradiation dosage equivalent to equal biologic effect: Sets 
of mice were inadiated with incrementally increasing dosages 
starting at ·o.5 MED a nd at 0.9 MED for each WG filter 
concentration. Tumor production occurred as shown in Figs 2 
and 3. Biologic responses were clinically and histologically 
similar for all filter combinations. All groups took approxi-
mately the same time (15-18 days) for tumors to be manifested . 
The salient results shown in Figs 2 and 3 are as follows: (1) 
The dosage at which the onset of tumorigenesis appears in-
creases with increasing filter thickness. (2) Tumors can be 
observed at lower total dosages for the 0.5 MED experiments 
than for the 0.9 MED experiments, except for the 3.0-mm filter 
study (see Discussion, however) . (3) In the early stages, a 
htgher percentage of tumors was produced in the 0.5 MED 
groups (except for the 3.0-mm filter combination) than for the 
0.9 MED group. However, many of these tumors regressed in 
the 0.5 MED group . Regression was not obvious in the 0.9 
MED group. All tumors that regressed were 3+ responses. (4) 
-:r:here are no straightforward relationsrups among tumor effi-
cie~cy.' dose fractionation, and spectral distribution of excitation 
radiatiOn. For example, the 1.0-mm filter combination appeal'ed 
to be most efficient at producing lasting tumors for both the 0.5 
MED and the 0.9 MED regimens. On the other hand, the 3.0-
mm combination appeared to be even more effi cient than the 
1.0-mm.comb~nation for the 0.9 MED regimen experiment, but 
was an meffic1ent carcinogen under the 0.5 MED regimen. 
DISCUSSION 
It. is apparen~ from these studies that the development of 
U~-mduced skm cancer is a complicated function of dose 
dehvery and spectral distribution of the excitation radiation 
but several salient points emerge. Fu·stly, tumors appear to b~ 
preferentially produced by shorter UVB wavelengths. The dos-
age at which the onset of tumorigenesis appears increases with 
increasing fil ter thickness. Since all groups took approximately 
the same time to develop their tumors, one might argue that 
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tt:mor initiation could actually occur relatively early with all 
doses, and that the time required for tumor growt h to the end 
point is the rate-limiting factor. In this interpretation , the 
shorter wavelengths would appeal' to be more efficient only 
because lower doses are being administered all along at these 
wavelengt~1s. Although such time factors undoubtedly play a 
~·ol~, the high potency of the short~,r wavelength per se is clearly 
md1cated by the results of the equal dose" experiment in 
which tumors were produced with "no filter" and 0.5-mm hlter 
combinations, but not with thicker filter combinations. 
Secondly, OUT results clearly emphasize that other factors are 
also of crit ical importance. More specifically, we found that 
tumorigenesis was markedly dependent on dose fractionation 
as has been observed by others [8]. In the "equal" dose exper~ 
iment, tumors or even earlier premalignant cha nges were not 
observed with total doses that would have produced such 
changes in the corresponding 0.5 MED and/or 0.9 MED exper-
iments. This latter observation underscores the lack of t ime-
dose reciprocity in the system a nd indicates that UV-induced 
tumor growth must compete with processes that can result in 
tumor regression. The existence of such processes can be fmther 
discel'ned from the "waxing and waning" behavior sh own in 
Figs 2 and 3 for the 0.5 MED dose-response curves. Some of 
the :'~ark" p1:ocesses mi.ght include or involve DNA repair, 
nutntwnal or 1mmunolog1c processes [1], as well as attenuation 
of damaging UV by stratum corneum thickening [6,11]. The 
early higher efficiency of the 0.5 MED vis-a-v is their 0.9 MED 
coun~erparts fm:ther suggests that t issue damage caused by 
burnmg may also compete with tumorigenesis. 
Thirdly, since UVA has been shown to augment UVB carci-
nogenesis [6], one might expect such augmentation to be of 
significant importance in these experiments, especially for the 
experiments involving thicker filters, in which both the UV A/ 
UVB ratio and the total dose al'e increased. Such an effect 
might contribute to the relatively high effi ciency of tumorigen-
esis shown by the 3.0 mm/0.9 MED regimen. On the other 
hand, UV A itself is a poor ca rcinogen.which may, under certain 
conditions, actually hinder UVB carcinogenesis through burn-
ing, necrosis, etc. Thus, there is a delicate balance between 
these two UV A effects; the net effect of UV A, in practice, 
probably represents a type of "vector sum" of these dynamic 
effects, which is determined for each experimental condition. 
In summary, the observable dose-response behavior for each 
regimen is a superimposition of "light" effects with the "dark" 
effects mentioned in the preceding paragraphs. This dose-re-
sponse behavior is very difficult to predict a priori. 
For any given filter combination, the differences in the 
tru·eshold doses for tumor response between the 0.5 and 0.9 
MED regimens (Figs 2, 3A-D) are significant inasmuch as these 
differences al'e larger than the estimated uncertainties of their 
measUl'ement. These uncertainties were calculated as follows: 
The tru·eshold dose for a response was considered to be some-
where between the total dose at which at least 1 tumor was 
observed and the previous total dose, where no tumors were 
observed. Under om· irradiation schedule, the incremental dose 
increase amounted to 6-7% of the total dose at which tumors 
were first observed for each filter condition; this r epresents the 
uncertainty of dose measul'ement given a precise knowledge of 
light intensity. The uncertainty of the latter measurement is 
estimated as ±10%. The combined uncertainty is estimated to 
be approximately 15%, which, as mentioned above, is smaller 
than the observed experimental differences between corre-
sponding 0.5 MED a nd 0.9 MED experiments. 
While it is not yet possible to quantitatively predict the effect 
of ozone depletion on tumor formation, evidence from these 
and other studies (6,8] is accumulating which might make 
possible limited quantitative predictions under a rigidly defined 
set of assumptions a nd experimental conditions. In general, the 
results suggest that increased availability of UV radiation 
tru·ough ozone depletion can significantly increase sec produc-
tion. On the other hand, if the doses al'e suff iciently prob:acted 
either by attenuating the flu ence rate or by increasing the 
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FIGS 2 AND 3. Dose-response of SK-1 haiJ"Iess mice irradiated wi th solar-simulating radiation (290-400 nm) filtered through Schott WG-320 
filters of va1·ious thicknesses. Fig 2, no Schott fil ter. Fig 3: A, 0.5-mm fi lter; B, 1.0-mm ftlter; C, 2.0-mm fil ter; D, 3.0-mm filter. Percent tumor 
response is the number of mice with 3+ response (see text) divided by the total number of mice X 100. In each figure, the dots correspond to the 
0.5 MED initial dose regimen, and the triang les correspond to the 0.9 MED regimen. 
" dark" periods between exposure at a given flue nce rate, factors 
that cause tumor suppression/ r egr ession as well as skin 
"hardening" could result in a significan t negation of t h ese 
effects. 
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